Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Eisai and FUJI YAKUHIN Conclude License Agreement
Details : Under this agreement, Eisai will proceed with the development of dotinurad in China.
Product Name : Urece
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 25, 2020
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Licensing Agreement